REGN — Regeneron Pharmaceuticals, Inc.

Is REGN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Regeneron Pharmaceuticals, Inc. (REGN) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $810.24. The rating moved from Neutral to Overbought on July 29, 2026.

See all overbought Healthcare stocks →

AI analysis

Regeneron combines durable cash flow from established biologics with a deep R&D engine and manufacturing scale, positioning it to capture upside from successful late‑stage readouts and increased demand for biologics supply chains. Financial health is solid with strong margins and a capable balance sheet that supports capital allocation flexibility. Key near‑term catalysts include clinical readouts and partnership announcements, while longer‑term growth hinges on pipeline progression and successful commercialization of new assets. Main vulnerabilities are payer/pricing pressure, regulatory outcomes, competitive dynamics and binary clinical risks that could materially affect the outlook.

Key factors

  • Diversified biologics portfolio with durable franchises (EYLEA, Dupixent collaboration) providing predictable cash flow and margins
  • Robust R&D pipeline across immunology, ophthalmology and oncology with multiple mid/late‑stage assets and BD/partnership optionality (mRNA/oncology readthroughs support sector tailwinds)
  • Exposure to a biologics/biotech supplier supercycle that could increase demand for CDMO/CRO services tied to successful mRNA/biologics programs
  • Strong balance sheet and free cash generation enabling share repurchases, M&A or additional partnership investments
  • Operational scale and in‑house manufacturing capabilities that support faster commercialization and margin retention versus smaller peers
  • Constructive near‑term market sentiment (risk‑on rotation) that may amplify upside into upcoming corporate news and sector catalysts

Risks

  • Payer and pricing pressure from insurers/PBMs and policy actions (coverage, formulary changes) that could compress realized prices and growth for high‑priced biologics
  • Clinical trial failures or delayed readouts across the pipeline that would materially reduce forward revenue visibility
  • Competition and biosimilar threats to core products over time (loss of exclusivity risk)
  • Regulatory and reimbursement uncertainty (FDA decisions, guidance changes, White House policy shifts affecting access and pricing)
  • Market volatility and macro/geopolitical headlines that can quickly reverse sentiment in large‑cap biotech
  • Concentration risk from a limited number of high‑revenue products—adverse events or safety issues could disproportionately impact top‑line

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for REGN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.